Related Experiment Videos
Antithrombotic therapy in native heart valve disease
1Klinik am See, Department of Cardiology, Rehabilitation Center of Cardiovascular Diseases, Seebad 84, D-15562 Rüdersdorf/Berlin, Germany. heinz.voeller@klinikamsee.com
Insights
Anticoagulation is recommended for patients with heart valve disease and atrial fibrillation (AF) or thromboembolic events. Differentiated approaches are needed for patients in sinus rhythm, considering specific risk factors for stroke.
Area of Science:
- Cardiology
- Neurology
- Vascular Medicine
Background:
- Native heart valve disease management requires distinguishing between patients with atrial fibrillation (AF) and those in sinus rhythm for anticoagulation decisions.
- Thromboembolic events and AF are primary indications for anticoagulation in non-valve replacement patients.
- Sinus rhythm patients require a nuanced approach based on specific cardiac conditions and risk factors.
Purpose of the Study:
- To outline differentiated anticoagulation strategies for patients with native heart valve disease.
- To clarify indications for anticoagulation in patients with sinus rhythm and specific cardiac conditions.
- To differentiate management of embolic sources in various valvular and congenital heart conditions.
Main Methods:
- Review of clinical guidelines and evidence for anticoagulation in native heart valve disease.
- Analysis of risk factors and embolic sources in patients with sinus rhythm.
- Comparison of anticoagulation indications based on specific valve pathologies (mitral stenosis, aortic stenosis) and congenital defects.
Main Results:
- Anticoagulation is indicated for thromboembolic events/AF unless valve replacement is performed.
- In sinus rhythm, anticoagulation (target INR 2.5) is indicated with left atrial enlargement, spontaneous echo contrast, absent atrial contraction, or reduced left ventricular function, particularly in mitral valve stenosis.
- Anticoagulation is not recommended for calcific microemboli in aortic stenosis; warfarin is indicated for aortic arch atherothrombotic plaques >5mm. Congenital lesions like MVP do not warrant anticoagulation alone, with aspirin recommended for secondary stroke prevention in MVP.
Conclusions:
- Anticoagulation decisions in native heart valve disease must be tailored to rhythm status and specific cardiac findings.
- Patients with sinus rhythm and specific risk factors (e.g., enlarged left atrium, impaired ventricular function) benefit from anticoagulation.
- Management of embolic risk varies significantly based on the underlying cause, with distinct strategies for valvular and congenital heart disease.
Abstract:
In establishing the indication for anticoagulation of patients with native heart valve disease, those with thromboembolic events and/or atrial fibrillation (AF) must be distinguished from patients with sinus rhythm. Anticoagulation should be started as a matter of principle in patients with thromboembolic events and/or AF who do not undergo valve replacement. However, a more differentiated procedure is mandatory for patients with sinus rhythm. If the left atrium is enlarged, spontaneous echo contrast is detected, and/or there is no atrial contraction and/or reduced left ventricular pump function (e.g., in patients with mitral valve stenosis), then anticoagulation with a target INR of 2.5 is indicated, even in those with sinus rhythm. Whereas rheumatic mitral valve stenosis predominates in developing countries, aortic stenosis (AS) predominates in developing countries. These AS patients mainly suffer microemboli that often determine the prognosis in patients with calcification of the mitral annulus. Anticoagulation is not recommended in calcific microemboli. If there are simultaneous atherothrombotic plaques of the aortic arch > 5 mm in size owing to an often more complex cardiovascular risk profile, then warfarin treatment is indicated. Mitral valve prolapse (MVP), patient foramen ovale and atrial septal aneurysm are potential sources of embolism that may cause stroke. On their own, these congenital lesions do not entail an indication for anticoagulation. This applies in particular to patients with MVP in whom secondary prevention of stroke can be attained with 100 mg aspirin.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:18Endocarditis III: Medical Management
01:21Rheumatic Heart Disease III: Medical Management
01:30Venous Thrombosis IV: Nursing Management